References

  1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-8
  2. Kelly B, Raphael B, Judd F, et al. Psychiatric disorder in HIV infection. Aust NZ J Psychiatry 1998; 32:441-53
  3. Adewuya AO, Afolabi MO, Ola BA, et al. Psychiatric disorders among the HIV-positive population in Nigeria: a control study. J Psychosom Res 2007; 63:203-6
  4. Thompson SC, Checkley GE, Hocking JS, et al. HIV risk behaviour and HIV testing of psychiatric patients in Melbourne. Aust NZ J Psychiatry 1997;31:566-76
  5. Whetten K, Reif S, Ostermann J, et al. Improving health outcomes among individuals with HIV, mental illness, and substance use disorders in the Southeast. AIDS Care 2006; 18(Suppl 1):S18-26 
  6. Di Clemente RJ, Ponton LE. HIV related risk behaviours among psychiatrically hospitalised adolescents and school based adolescents. Am J Psychiatry 1993; 150 324-5
  7. Smith MD. HIV risk in adolescents with severe mental illness. J Adolesc Health 2001; 29:320-9
  8. Cohen MA, Cozza KL, Bourgeois JA, et al, and the Academy of Psychosocial Medicine.  The role of psychiatrists in HIV prevention.  Psychiatric Times. March 2016; 33:30-2.
  9. Friedman MS, Marshal MP, Stall R, et al. Gay-related development, early abuse and adult health outcomes among gay males. AIDS Behav 2008; 12:891-902
  10. Cochran SD, Mays VM, Sullivan JG. Prevalence of mental disorders, psychological distress, and mental health services use among lesbian, gay, and bisexual adults in the United States. J Consult Clin Psychol 2003; 71 :53-6
  11. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2015. Sydney: The Kirby Institute, UNSW; 2015. Available at: https://kirby.unsw.edu.au/sites/default/files/hiv/resources/ASR2015_v3.pdf (last accessed January 2016). The Kirby Institute Australian HIV Surveillance Report. Vol 29 No 2 April 2013. The University of NSW. www.kirby.unsw.edu.au 
  12. Cohen M, Arad S, Lorber M, et al. Psychological distress, life stressors, and social support in new immigrants with HIV. Behav Med 2007; 33:45-54
  13. Draguns JG, Tanaka-Matsumi J. Assessment of psychopathology across and within cultures: issues and findings. Behav Res Ther 2003; 41:755-76
  14. Poulsen HD, Lublin HK. Efavirenz-induced psychosis leading to involuntary detention. AIDS 2003; 17:451-3
  15. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158:725-30
  16. Atkinson JH, Heaton RK, Patterson TL, et al. Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord 2008; 108:225-34
  17. Stolar A, Catalano G, Hakala SM, et al. Mood disorders and psychosis in HIV. In: Citron K, Brouillette MJ, Beckett A (editors). HIV and Psychiatry. 2nd rev. ed. Cambridge, 2005:88-109
  18. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007; 21:1175-83
  19. von Ammon Cavanaugh S, Furlanetto LM, Creech SD, et al. Medical illness, past depression, and present depression: a predictive triad for in-hospital mortality. Am J Psychiatry 2001; 158:43-8
  20. Clark DC, Cavanaugh SV, Gibbons RD. The core symptoms of depression in medical and psychiatric patients. J Nerv Ment Dis 1993; 167:705-13
  21. Olatunji BO, Mimiaga MJ, O’Cleirigh C, et al. Review of treatment studies of depression in HIV. Top HIV Med 2006; 14:112-24
  22. Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry 1994; 55:433-9
  23. Sewell MC, Goggin KJ, Rabkin JG, et al. Anxiety syndromes and symptoms among men with AIDS: a longitudinal controlled study. Psychosomatics 2000; 41:294-300
  24. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-8
  25. Radcliffe J, Fleisher CL, Hawkins LA, et al. Posttraumatic stress and trauma history in adolescents and young adults with HIV. AIDS Patient Care STDS 2007; 21:501-8
  26. Andrews G, Creamer M, Crino R, et al. The Treatment of Anxiety Disorders. 2nd Edition. Cambridge University Press, 2003
  27. Ellen SR, Judd FK, Mijch AM, et al. Secondary mania in patients with HIV infection. Aust NZ J Psychiatry 1999; 33:353-60
  28. Cruess DG, Evans DL, Repetto MJ, et al. Prevalence, diagnosis and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003; 54:307-16
  29. Stolar A, Catalano G, Hakala SM, et al. Mood disorders and psychosis in HIV. In: Citron K, Brouillette MJ, Beckett A (editors). HIV and Psychiatry. 2nd rev. ed. Cambridge, 2005:88-109
  30. Ellen SR, Judd FK, Mijch AM, et al. Secondary mania in patients with HIV infection. Aust NZ J Psychiatry 1999; 33:353-60
  31. Cruess DG, Evans DL, Repetto MJ, et al. Prevalence, diagnosis and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003; 54:307-16
  32. Ellen SR, Judd FK, Mijch AM, et al. Secondary mania in patients with HIV infection. Aust NZ J Psychiatry 1999; 33:353-60
  33. Ferrando SJ,Tiamson-Kassab MLA. HIV Disease. In: Blumenfield M. Strain JJ (editors). Psychosomatic Medicine. Lippincott, Williams and Wilkins: 2006, 277-96
  34. Uldall KK, Ryan R, Berghuis JP, et al. Association between delirium and death in AIDS patients. AIDS Patient Care STDS 2000; 14:95-100
  35. Judd FK. Delirium in the consultation setting. Int Rev Psychiatry 1996; 8:259-66
  36. Breitbart W, Marotta R, Platt MM, et al. A double blind trial of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231-7
  37. Fischer-SmithT, Rappaport J. Evovling paradigms in the pathogenesis of HIV-1 associated dementia. Expert Rev Mol Med. 2005; 7:1-26
  38. Ghafouri M, Amini S, Khalili K, et al.HIV-1 associated dementia: symptoms and causes. Retrovirology 2006; 3:28
  39. Tedaldi EM, Minniti NL, Fischer T. HIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbidities. Biomed Res Int 2015; 2015:641913
  40. Cysique LA, Bain MP, Lane TA, et al. Management issues in HIV-associated neurocognitive disorders. Neurobehavior HIV Med 2012; 4:63-73
  41. Antorini A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-99
  42. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-96
  43. Saktor NC, Lyles RH, Skolasky RL, et al. HIV associated neurological disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-60
  44. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-8
  45. Prochaska JO, di Clemente CC. The transtheoretical approach: crossing traditional boundaries of therapy. Homewood ILL: Dorsey Professional Books: 1984
  46. Thompson A, Silverman B, Dzeng L, et al. Psychotropic medications and HIV. Clin Infect Dis 2006; 42:1305-10
  47. Mollan KR, Smurzynski M, Eron JJ et al: Association between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk of Suicidal Ideation, Attempted, or Completed Suicide. Ann Intern Med. 2014; 161:1-10.